SRC inhibitor saracatinib enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

被引：0
|
作者：
Lu, Fei-Teng [1 ]
Luo, Fan [1 ]
Qiu, Miao-Zhen [1 ]
Cao, Jia-Xin [1 ]
Luo, Qiu-Yun [1 ]
Yang, Da-Jun [2 ]
Zhao, Hong-Yun [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ascentage Pharma Suzhou Co Ltd, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6094
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Shimoda, Yukiko
    Takayanagi, Daisuke
    Shiraishi, Kouya
    Kubo, Takashi
    Mitani, Sachiyo
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Ichikawa, Hitoshi
    Kohno, Takashi
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Motoi, Noriko
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer
    Tsoukalas, Nikolaos
    Kiakou, Maria
    Tsapakidis, Konstantinos
    Tolia, Maria
    Aravantinou-Fatorou, Eleni
    Baxevanos, Panagiotis
    Kyrgias, Georgios
    Theocharis, Stamatios
    JOURNAL OF BUON, 2019, 24 (03): : 883 - 888
  • [23] Multidimensional Signature of Immune Cell Abundance and Spatial Location Predicts the Efficacy of PD-1/PD-L1 Blockade Therapy in Advanced Non-Small Cell Lung Cancer
    Hu, Zijuan
    Hu, Zhihuang
    Zhou, Xiaoyan
    Wei, Ping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1917 - S1917
  • [24] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [25] Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
    Mussafi, Ofek
    Mei, Jie
    Mao, Wenjun
    Wan, Yuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [27] Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer
    Zhu, Zhongxiu
    Zhang, Aixia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (11): : 496 - 502
  • [28] PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
    Peng, Zikun
    Li, Ming
    Li, Huayi
    Gao, Qinglei
    DRUG DISCOVERY TODAY, 2023, 28 (08)
  • [29] Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer
    Kim, Hye In
    Kim, Won Gu
    Kim, Mijin
    Ko, Nak Gyeong
    Jin, Mihyeon
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Choi, Yoon-La
    Jeon, Min Ji
    Kim, Tae Yong
    Kim, Won Bae
    Kim, Sang-We
    Lee, Dae Ho
    Jang, Se Jin
    Kim, Sun Wook
    Chung, Jae Hoon
    Kim, Tae Hyuk
    Lee, Se-Hoon
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [30] Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    He, Jiabei
    Hu, Ying
    Hu, Mingming
    Li, Baolan
    SCIENTIFIC REPORTS, 2015, 5
12345